Product Pipeline
Custom Pages

Product Pipeline

The safety and pharmacological activity of CGX1321 have inspired a pipeline of novel therapies for various indications that capitalizes the fundamental WNT biology in cancer and tissue repair/regeneration. In addition to the ongoing clinical trials, Curegenix plans to advance at least three additional programs into clinical trials over the next three years for oncology, fibrosis and cartilage regeneration where WNT inhibitors have shown clinical or preclinical activities.

Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.

Get In Touch with Curegenix

    Copyright 2021 Curegenix Corporation | All Rights Reserved